Background and aim: Human papillomavirus (HPV) is sexually transmitted, one of the three
most common sexually transmitted infections (STIs) in both males and females, and the most …

Vaccine efficacy determined within the controlled environment of a clinical trial is usually
substantially greater than real-world vaccine effectiveness. Typically, this results from …

Summary Background An Escherichia coli-produced human papillomavirus (HPV) 16 and
18 bivalent vaccine (Cecolin) was prequalified by WHO in 2021. This study aimed to …

The Escherichia coli-produced human papillomavirus (HPV) 16/18 bivalent vaccine
(Cecolin) has received prequalification by the World Health Organization based on its high …

Human papillomavirus (HPV) infection is the most common sexually transmitted infection,
with up to 90% of individuals infected with HPV at some point in their lives (1). While most …

Although HPV vaccines are highly efficacious, a notable proportion of quadrivalent
vaccinees are HPV18 seronegative post-vaccination. We have investigated this findings' …

Seroepidemiological characteristics of human papillomavirus (HPV) in community residents
reflect natural infection and can guide the reform of vaccination programs. A population …

The vast majority of antibodies generated against a virus will be non-neutralising. However,
this does not denote an absence of protective capacity. Yet, within the field, there is typically …

The human papillomavirus (HPV) vaccine was initially approved for a three-dose regimen.
Due to resource limitations, budget constraints, low acceptance, and poor adherence, global …

Neutralizing antibodies (NAbs) are considered the primary mechanism of vaccine‐mediated
protection against human papillomaviruses (HPV), the causative agent of cervical cancer …